Neurovascular Thrombectomy Devices Market Size, Share and Trends 2025 to 2034

Revenue, 2024

USD 773.26 Mn

Forecast Year, 2034

USD 1,494.32 Mn

CAGR, 2025 - 2034

6.81%

Report Coverage

Global

What is the Neurovascular Thrombectomy Devices Market Size?

The global neurovascular thrombectomy devices market size accounted for USD 825.92 million in 2025 and is predicted to increase from USD 882.16 million in 2026 to approximately USD 1,494.32 million by 2034, expanding at a CAGR of 6.81% from 2025 to 2034. This market is growing due to the increasing prevalence of neurovascular disorders and the rising adoption of minimally invasive treatments.

Market Highlights

• North America dominated the sector, holding the largest market share of 44.2% in 2024.
• Asia Pacific is expected to grow at a solid CAGR of 12.6% from 2025 to 2034.
• By product type, the stent retrievers segment held the largest share of 45.8% in 2024.
• By product type, the aspiration catheters segment is growing at a solid CAGR of 11.4% from 2025 to 2034.
• By usability, the reusable devices segment contributed the biggest market share of 71.5% in 2024.
• By application, the ischemic stroke segment recorded the highest market share of 68.8% in 2024.
• By application, the hemorrhagic stroke segment is expanding at the fastest CAGR from 2025 to 2034.
• By end user, the hospitals segment held the biggest market share of 42.8% in 2024.
• By end user, the ambulatory surgical centers segment is poised to grow at a notable CAGR of 12% from 2025 to 2034.

Thrombectomy Devices Pulse: Thriving in the Next Decade

The neurovascular thrombectomy devices market is experiencing significant growth, motivated by the growing need for minimally invasive procedures and the increasing incidence of neurovascular disorders. Innovations in technology, like energy-based thrombectomy systems, miniaturized catheters, and improved imaging integration, are enhancing patient safety and procedure results. Along with the expansion of already existing businesses, the market is also seeing the entry of new players.

• In July 2025, Q'Apel Medical announced U.S. FDA clearance for its Zebra Neurovascular Access System. This system is designed for the introduction of interventional devices into the peripheral and neurovasculature, providing enhanced support and stability during procedures.

How to Reignite Value Creation in Large, Diversified Medtechs

• Miniaturized and Flexible Catheters: Access to complex neurovascular areas is made possible by the development of smaller, more flexible catheters, which lowers the risk of procedures. Treating complex thrombotic disorders is made possible by miniaturization, which enables easier access to previously unreachable locations and the negotiation of convoluted vessels.
• Robotic-assisted Navigation: When performing intricate neurovascular procedures, new robotic-assisted delivery systems increase precision and lessen operator fatigue. Robots make it possible to move and position devices to move and position devices precisely, which is essential in the delicate brain vasculature. Additionally, they make it possible to operate remotely, increasing access to specialized care in underprivileged areas.

Neurovascular Thrombectomy Devices Market Outlook

[[market_outlook]]

Market Scope

Restraint

Shortage of Skilled Specialists

For the safe and efficient use of these devices, neurovascular procedures are extremely complex and call for skilled specialists. Expert neuro interventionalists are in short supply worldwide, especially in developing nations. The expansion of the thrombectomy procedures is restricted by this shortage of skilled workers, which also slows the market's growth rate. The availability of specialists and ongoing training initiatives continues to bea major obstacle.

Opportunity

Technological Advancements and Smart Devices

Robotic guidance, AI-assisted navigation, and IoT-enabled monitoring are examples of emerging technologies that are improving procedural safety and accuracy. Devices that incorporate intelligent feedback systems and real-time imaging can improve clinical outcomes, giving device manufacturers new opportunities to stand out from the competition.

Neurovascular Thrombectomy Devices MarketSegmental Insights

[[segment_insights]]

Neurovascular Thrombectomy Devices MarketRegional Insights

[[regional_insights]]

Country-Level Investments/Funding Trends for Neurovascular Thrombectomy Devices Market

Neurovascular Thrombectomy Devices Market Companies

[[market_company]]

Other Companies in the Neurovascular Thrombectomy Devices Market

• Penumbra, Inc .: Penumbra, Inc. is a global leader in neurovascular thrombectomy technologies, specializing in innovative aspiration and mechanical thrombectomy systems for ischemic stroke treatment. Its Penumbra System and RED reperfusion catheters are widely adopted for rapid and effective clot removal. The company's continuous focus on expanding its Indigo and Lightning platforms underscores its leadership in neuro-interventional innovation and minimally invasive stroke care.
• Johnson & Johnson (Cerenovus): Cerenovus, a division of Johnson & Johnson MedTech, offers a comprehensive neurovascular portfolio including EmboTrap Revascularization Device and Cerenovus Stroke Solutions. The company invests heavily in stroke research, focusing on clot science and advanced thrombectomy tools designed to improve patient outcomes and procedural efficiency. Its integrated ecosystem supports both acute ischemic stroke and hemorrhagic treatment solutions.
• Terumo Corporation: Terumo Corporation develops high-precision neurovascular intervention devices, including microcatheters, guidewires, and stent retrievers. Its solutions are designed for both aspiration and stent-based thrombectomy. The company's R&D emphasis on catheter control and navigability enhances procedural safety in complex neurovascular anatomies.
• MicroVention, Inc. (a Terumo Company): MicroVention, a subsidiary of Terumo, specializes in neuroendovascular technologies for stroke and aneurysm management. Its Sofia and Trevo systems are recognized for advanced clot retrieval performance. MicroVention's integration of imaging, materials science, and catheter innovation reinforces its global influence in minimally invasive neurotherapies.
• Boston Scientific Corporation: Boston Scientific provides a robust range of neurovascular devices, including stent retrievers and aspiration systems used in mechanical thrombectomy. Its VAXTON and SYMPHONY platforms focus on improving revascularization speed and success rates. The company's strong global distribution and clinical research programs strengthen its market presence in stroke intervention technologies.
• Acandis GmbH: Acandis GmbH specializes in neuro-interventional devices such as stent retrievers and flow diverters, designed for the treatment of ischemic stroke and aneurysms. The company focuses on European markets with CE-certified thrombectomy solutions emphasizing precision and biocompatibility.
• Phenox GmbH (Wallaby Medical): Phenox, now part of Wallaby Medical, manufactures advanced neurovascular devices including pRESET and pRESET LITE stent retrievers. The company's innovation centers on enhancing vessel access, clot engagement, and procedural outcomes.
• Rapid Medical Ltd.: Rapid Medical is known for its TIGERTRIEVER device the first adjustable stent retriever designed for real-time control during thrombectomy. The company's technology provides greater adaptability to diverse clot morphologies and vessel anatomies, improving safety and efficacy in stroke interventions.
• Vesalio, LLC: Vesalio develops the NeVa platform, a proprietary stent retriever system engineered for high clot capture and full-vessel restoration. The company emphasizes mechanical innovation and simplicity for faster, more consistent stroke treatment.
• Balt Group: Balt Group designs and manufactures neurovascular access, embolization, and thrombectomy devices. Its solutions combine precision engineering and innovative materials for improved revascularization outcomes in complex neurointerventional procedures.
• Imperative Care, Inc.: Imperative Care offers a novel portfolio of stroke treatment devices, including the Zoom Thrombectomy System. Its focus on procedural efficiency, device versatility, and post-stroke recovery solutions demonstrates a comprehensive approach to neurovascular care.
• Asahi Intecc Co., Ltd.: Asahi Intecc manufactures high-performance guidewires and microcatheters essential for neurovascular interventions. Its precision engineering and wire technology are crucial for safe navigation in delicate cerebral vasculature.
• Kaneka Corporation: Kaneka produces polymer-based neurovascular devices, including microcatheters and embolization materials. The company's research-driven innovations enhance device flexibility and control for safe, effective stroke interventions.

Segments Covered in the Report

[[segment_covered]]